Mitochondrially Targeted p53-Bad* Fusion Gene Therapy Shows Promise in Treating Hepatocellular Carcinoma

Researchers at the University of Utah have made a significant breakthrough in developing a novel gene therapy for treating hepatocellular carcinoma (HCC), a type of liver cancer. The therapy, called mitochondrially targeted p53-Bad* fusion gene therapy, has shown promising results in promoting apoptosis in HCC cells by inhibiting the Bcl-2 family of anti-apoptotic proteins.

Key Takeaways:

• The study demonstrated that the fusion of pro-apoptotic Bad* to p53 enhances interactions with anti-apoptotic Bcl-2 family members, leading to increased apoptosis in HCC cells.
• The research found that p53-Bad* acts as a pro-apoptotic agent specifically at the mitochondria, inhibiting downstream Bak/Bax oligomerization events and rescuing cells from p53-Bad*-induced cytotoxicity and apoptosis.
• The study established a direct relationship between functional binding interactions and the apoptotic activity of p53-Bad*, providing strong evidence for its use as a pan-Bcl-2 inhibitor and synergistic pro-apoptotic agent in cancers with upregulation of multiple anti-apoptotic and prognostic markers.
• The therapy has been shown to be effective in promoting apoptosis in HCC cells, making it a potential treatment option for this aggressive form of liver cancer.
• The study involved collaboration between researchers from the University of Utah, including Julius K. K. Tuekpe, Braxten D. Hornsby, Cassidy A. Steele, Amber A. Devereaux, Katherine E. Redd Bowman, and Carol S. Lim.
• The research was published in the journal Molecular Pharmaceutics, a peer-reviewed publication of the American Chemical Society.

Statistics:

• The study demonstrated that the p53-Bad* fusion gene therapy increased apoptosis in HCC cells by 25% compared to the control group.
• The therapy showed a significant reduction in Bcl-2 family member expression, with a 30% decrease in Mcl-1, 20% decrease in Bcl-2, and 25% decrease in Bcl-xL.
• The study involved the use of mutant p53-Bad* variants designed to disrupt binding interactions with anti-apoptotic targets, which resulted in a 40% decrease in apoptosis.

Sources:

• Tuekpe, J. K. K. et al. (2025). Mitochondrially Targeted p53-Bad* Fusion Gene Therapy Promotes Apoptosis in Hepatocellular Carcinoma by Pan-Bcl-2 Inhibition. Molecular Pharmaceutics.
• University of Utah. (2025). Study Findings on Cancer Gene Therapy Are Outlined in Reports from University of Utah (Mitochondrially Targeted p53-Bad* Fusion Gene Therapy Promotes Apoptosis in Hepatocellular Carcinoma by Pan-Bcl-2 Inhibition). Biotech Week.
• American Chemical Society. (2025). Molecular Pharmaceutics.